Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

PURPOSE: Clinical trials have shown a significant increase in pathologic complete response (pCR) with the addition of pertuzumab to neoadjuvant chemotherapy for patients with early-stage HER-2 positive breast cancer. To date, limited studies have examined comparative outcomes of neoadjuvant pertuzum...

Descripción completa

Detalles Bibliográficos
Autores principales: Fabbri, Agnese, Nelli, Fabrizio, Botticelli, Andrea, Giannarelli, Diana, Marrucci, Eleonora, Fiore, Cristina, Virtuoso, Antonella, Scagnoli, Simone, Pisegna, Simona, Alesini, Daniele, Sini, Valentina, Orlandi, Armando, Fabi, Alessandra, Piacentini, Federico, Moscetti, Luca, D’Auria, Giuliana, Gamucci, Teresa, Mazzotta, Marco, Pizzuti, Laura, Vici, Patrizia, Cretella, Elisabetta, Scavina, Paola, La Cesa, Annalisa, Persano, Mara, Atzori, Francesco, Ruggeri, Enzo Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335743/
https://www.ncbi.nlm.nih.gov/pubmed/37441419
http://dx.doi.org/10.3389/fonc.2023.1177681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10335743/
https://www.ncbi.nlm.nih.gov/pubmed/37441419
http://dx.doi.org/10.3389/fonc.2023.1177681

Ejemplares similares